SCHEMBL8725911

SCHEMBL8725911

O=C(Nc1ccc2scc(C3CCC4CCCCN4CC3)c2c1)c1cccc([N+](=O)[O-])c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.45
KMT2A Q03164 5/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
SIRT2 Q8IXJ6 1/20 0.43
MAPT P10636 4/20 0.42
POLB P06746 2/20 0.42
BLM P54132 1/20 0.42
HTR1A P08908 1/20 0.42
HTR1D P28221 1/20 0.42
HTR1B P28222 1/20 0.42
HTR1F P30939 1/20 0.42
THRA P10827 1/20 0.41
CASP3 P42574 2/20 0.41
GAA P10253 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
SETD7 Q8WTS6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8725928 0.87 RORC (0.47) MEN1KMT2AL3MBTL1NPC1RAB9A
SCHEMBL8724094 0.82 ACKR3 (0.39) KMT2AL3MBTL1NPC1RAB9AHTR1A
SCHEMBL8723856 0.82 HTR1D (0.50) NPC1RAB9AHTR1AHTR1DHTR1B
SCHEMBL8552657 0.82 L3MBTL1 (0.49) MEN1KMT2AL3MBTL1NPC1RAB9A
SCHEMBL8721836 0.81 TMIGD3 (0.41) L3MBTL1RAB9AHTR1AHTR1DHTR1B
SCHEMBL8721254 0.81 TDP1 (0.38) MEN1KMT2AL3MBTL1NPC1RAB9A
SCHEMBL8721795 0.81 KMT2A (0.46) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL8723979 0.81 MAPT (0.41) MEN1KMT2AL3MBTL1MAPTHTR1A
SCHEMBL8720774 0.80 L3MBTL3 (0.43) L3MBTL1RAB9AHTR1AHTR1DHTR1B
SCHEMBL8721187 0.80 TDP1 (0.38) MEN1KMT2AL3MBTL1MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ LP (CA) 2026-05-07 US disclosed
WO-2024073845-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ, LIMITED PARTNERSHIP (CA) 2024-04-11 WO disclosed
EP-0875513-A1 Substituted heteroaromatic 5-HT 1F agonists ELI LILLY AND COMPANY (US) 1998-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS HTR1F, HTR1A, HTR1D MEN1 458/4885KMT2A 2708/4885L3MBTL1 415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.